Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1023557

Contents of this Issue

Navigation

Page 7 of 51

SPONSORED CONTENT 6 Clinical OMICs September/October 2018 www.clinicalomics.com The Genomic Edge: New Tools Provide New Advantages Genomics is Providing an Important Competitive Advantage For Leading Medical Facilities and Drug Developers Thousands of children with "mysterious" health problems are now receiving genetic diagnoses every year thanks to a groundbreaking sequencing partnership between WuXi NextCODE and Fudan Children's Hospital in Shanghai, China. With Boston Children's Hospital, meanwhile, we are going to analyze the DNA of 3,000 epilepsy and inflammatory bowel disease patients and family members. And, at the University of Pittsburgh Medical Center's (UPMC) new genome center, cancer patients receiving immunotherapy will have their tumors sequenced and analyzed, again using WuXi NextCODE's advanced analytical tools. These are just a few examples of how genomics is transforming medicine. Thanks to advances in sequencing and related tools, any facility that treats patients or has stored biological samples can now provide state-of-the art care or conduct cutting-edge research. It's not just because sequencing has become much less expensive, faster, and more accurate. An array of supportive tools has also been built that help researchers get much more value out of genomic data. These include: • Highest quality advanced sequencing, including rapid whole genome, exome, single cell, and long-read analysis • A growing number of public and private genomic databases, which can be used for target and biomarker discovery, as well as to select optimal cohorts for clinical trials • The GOR data analysis platform, which allows querying of multiple data types and their integration • Our breakthrough DNA isolation technique (SeqPlus™) for FFPE samples • New analytical methods, including artificial intelligence (AI), that make it possible to integrate multiple types of omic and other biological data to uncover the real biological drivers of disease. While many groups offer advanced sequencing capabilities, WuXi NextCODE has some unique add-on tools, as well as the ability to offer the entire range from "sample analysis through actionable insight." (Figure 1) We provide CLIA- and CAP-certified sequencing, for germline and cancer samples, both fresh frozen as well as FFPE samples. We are also expert in primary through tertiary data analysis and have advanced tools for drawing the maximum value from your data, including statistical machine learning and artificial intelligence. Our services are available via the leading global cloud providers, making your workflow quicker and easier. Features that make us stand out include: The GOR Analytical Pipeline The GOR genomically ordered relational database has touched more genomes than any other data analysis platorm over the last two decades. It was developed in Iceland on the world's largest whole-genome sequence dataset and is the solution of choice for Figure 1. The full range of genomic analysis

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018